- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01604850
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)
A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 4Z6
- University Of Calgary
-
Edmonton, Alberta, Canadá, T6G 2X8
- University of Alberta Hospital
-
Edmonton, Alberta, Canadá, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1M9
- Gordon & Leslie Diamond Health Care Centre
-
Vancouver, British Columbia, Canadá, V6Z 2C9
- University of British Columbia
-
Vancouver, British Columbia, Canadá, V6Z 2K5
- (G.I.R.I.) Gastrointestinal Research Institute
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 3P4
- University of Manitoba Health Sciences Center
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H 8L6
- The Ottawa Hospital
-
Toronto, Ontario, Canadá, M5T 2S8
- Toronto Western Hospital
-
Toronto, Ontario, Canadá, M6H 3M1
- Toronto Liver Centre
-
Toronto, Ontario, Canadá, M5G 1X5
- Mount Sinai Hospital
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 3J4
- Hopital St. Luc
-
-
-
-
California
-
Coronado, California, Estados Unidos, 92118
- Scti Research Foundation
-
Los Angeles, California, Estados Unidos, 90027
- Kaiser Permanente
-
Los Angeles, California, Estados Unidos, 90036
- Peter J. Ruane, MD, Inc.
-
Los Angeles, California, Estados Unidos, 90069
- Anthony Mills MD, Inc.
-
San Diego, California, Estados Unidos, 92123
- Medical Associates Research Group, Inc.
-
San Diego, California, Estados Unidos, 92103
- UCSD Antiviral Research Center
-
San Diego, California, Estados Unidos, 92154
- Kaiser Permanente
-
San Francisco, California, Estados Unidos, 94115
- Quest Clinical Research
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado
-
Englewood, Colorado, Estados Unidos, 80113
- South Denver Gastroenterology, PC
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20009
- Whitman Walker Clinic
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610-0277
- University of Florida
-
Jacksonville, Florida, Estados Unidos, 32256
- Borland-Groover Clinic Baptist
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
New Port Richey, Florida, Estados Unidos, 34653
- Advanced Research Institute
-
Orlando, Florida, Estados Unidos, 32806
- Internal Medicine Specialists
-
Orlando, Florida, Estados Unidos, 32803-1851
- Orlando Immunology Center (ACH)
-
Wellington, Florida, Estados Unidos, 33414
- South Florida Center of Gastroenterology, P.A.
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30309
- Digestive Healthcare of Georgia
-
Marietta, Georgia, Estados Unidos, 30060
- Gastrointestinal Specialists of Georgia, PC
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46237
- Indianapolis Gastroenterology Research Foundation
-
-
Kentucky
-
Bowling Green, Kentucky, Estados Unidos, 42101
- Graves-Gilbert Clinic
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Gastroenterology Associates, LLC
-
-
Maryland
-
Lutherville, Maryland, Estados Unidos, 21093
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114-2696
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02115
- Beth Israel Deaconess Medical Center
-
Springfield, Massachusetts, Estados Unidos, 01105
- The Research Institute
-
-
Michigan
-
Novi, Michigan, Estados Unidos, 48377
- Henry Ford Health System
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55414
- Minnesota Gastroenterology, P.A.
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64131
- Kansas City Gastroenterology and Hepatology
-
-
New Jersey
-
Berlin, New Jersey, Estados Unidos, 08009
- Comprehensive Clinical Research
-
Hillsborough, New Jersey, Estados Unidos, 08844
- ID Care
-
-
New Mexico
-
Santa Fe, New Mexico, Estados Unidos, 87505
- Southwest C.A.R.E. Center
-
-
New York
-
Binghamton, New York, Estados Unidos, 13903
- Binghamton Gastroenterology Associates
-
New York, New York, Estados Unidos, 10029
- Mount Sinai School of Medicine
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Asheville Gastroenterology Associates, P.A.
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Digestive Health Specialists, PA
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02906
- The Miriam Hospital
-
Providence, Rhode Island, Estados Unidos, 02905
- University Gastroenterology
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Gastro One
-
Nashville, Tennessee, Estados Unidos, 37211
- Nashville Gastrointestinal Specialists, Inc
-
-
Texas
-
Arlington, Texas, Estados Unidos, 76012
- Texas Clinical Research Institute, LLC
-
Dallas, Texas, Estados Unidos, 75219
- Southwest Infectious Disease Clinical Research, Inc.
-
San Antonio, Texas, Estados Unidos, 78215
- Alamo Medical Research
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Metropolitan Research
-
Falls Church, Virginia, Estados Unidos, 22042
- Inova Fairfax Hospital Center for Liver Diseases
-
Norfolk, Virginia, Estados Unidos, 23502
- Digestive and Liver Disease Specialists
-
Richmond, Virginia, Estados Unidos, 23226
- Bon Secours St. Mary's Hospital of Richmond, Inc.
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Virginia Mason Medical Center
-
-
-
-
-
Auckland, Nueva Zelanda, 1640
- Auckland Clinical Studies Limited
-
Christchurch, Nueva Zelanda, 8011
- Christchurch Hospital
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Fundacion De Investigacion de Diego
-
San Juan, Puerto Rico, 00909-1711
- Clinical Research Puerto Rico Inc
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Infection with HCV genotype 2 or 3
- Had cirrhosis determination
- Prior treatment failure
- Screening laboratory values within defined thresholds
- Subject had not been treated with any investigational drug or device within 30 days of the screening visit
- Use of highly effective contraception methods if female of childbearing potential or sexually active male
Exclusion Criteria:
- Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase
- Pregnant or nursing female or male with pregnant female partner
- Current or prior history of clinical hepatic decompensation
- History of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol
- Excessive alcohol ingestion or significant drug abuse
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: SOF+RBV+placebo
Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
|
Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
Otros nombres:
Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Placebo to match SOF was administered orally once daily.
Placebo to match RBV was administered orally twice daily.
|
Experimental: SOF+RBV
Participants were randomized to receive SOF+RBV for 16 weeks.
|
Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
Otros nombres:
Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants Achieving SVR12
Periodo de tiempo: Posttreatment Week 12
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ, ie, < 25 IU/mL) 12 weeks after cessation of therapy. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Posttreatment Week 12
|
Adverse Events Leading to Permanent Discontinuation of Study Drug
Periodo de tiempo: Baseline to Week 16
|
Adverse events which led to permanent discontinuation of study drug may or may not have been related to study treatment.
|
Baseline to Week 16
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants Achieving SVR4
Periodo de tiempo: Posttreatment Week 4
|
SVR4 was defined as HCV RNA < LLOQ 4 weeks after cessation of therapy. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Posttreatment Week 4
|
Percentage of Participants Achieving SVR24
Periodo de tiempo: Posttreatment Week 24
|
SVR24 was defined as HCV RNA < LLOQ 24 weeks after cessation of therapy. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Posttreatment Week 24
|
Percentage of Participants With Viral Breakthrough
Periodo de tiempo: Up to 16 weeks
|
Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values. For the purposes of this efficacy analysis, assessments were made during active treatment (up to Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Up to 16 weeks
|
Percentage of Participants With Viral Relapse
Periodo de tiempo: End of treatment to posttreatment Week 24
|
Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
End of treatment to posttreatment Week 24
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, Hunt SL. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. J Infect Dis. 2015 Aug 1;212(3):367-77. doi: 10.1093/infdis/jiv005. Epub 2015 Jan 12.
- Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014 Sep;40(6):676-85. doi: 10.1111/apt.12880. Epub 2014 Jul 15.
- Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades del HIGADO
- Infecciones por Flaviviridae
- Hepatitis, Viral, Humana
- Hepatitis Crónica
- Hepatitis
- Hepatitis C
- Hepatitis C Crónica
- Agentes antiinfecciosos
- Agentes Antivirales
- Sofosbuvir
Otros números de identificación del estudio
- GS-US-334-0108
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Hepatitis C Crónica
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC)Estados Unidos, Australia, Canadá, Francia, Alemania, Nueva Zelanda, Puerto Rico, España, Reino Unido
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC) | Infección viral de la hepatitis CEstados Unidos, Nueva Zelanda
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 4 | Infección viral de la hepatitis CEstados Unidos
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
AbbVieTerminadoVirus de la hepatitis C | Virus de la hepatitis C crónica
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos
-
Humanity and Health Research CentreBeijing 302 HospitalTerminadoInfección crónica por hepatitis CPorcelana
-
University Health Network, TorontoTerminadoInfección crónica por hepatitis CCanadá
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos, Puerto Rico
Ensayos clínicos sobre SOF
-
McMaster UniversityAgency for Healthcare Research and Quality (AHRQ); Grading of Recommendations...Terminado
-
Sanjay Gandhi Postgraduate Institute of Medical...Ram Manohar Lohia Institute of Medical Sciences, LucknowTerminado
-
Amp Orthopedics, Inc.TerminadoOsteoartritis de rodillaEstados Unidos
-
Humanity & Health Medical Group LimitedRetiradoInfección por VHCHong Kong
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical UniversityReclutamientoInfección crónica por hepatitis CPorcelana
-
Stanford UniversityEndonovoReclutamientoDolor Postoperatorio | Lesiones de hombro | Lesiones de rodillaEstados Unidos
-
Humanity and Health Research CentreBeijing 302 HospitalTerminadoInfección crónica por hepatitis CPorcelana
-
Gilead SciencesTerminadoInfección por el virus de la hepatitis CFrancia, España, Estados Unidos, Australia, Canadá, Alemania, Reino Unido, Italia, Nueva Zelanda, Puerto Rico
-
Gilead SciencesTerminadoInfección por el virus de la hepatitis CEstados Unidos, Puerto Rico
-
Stanford UniversityGilead SciencesTerminado